Addition of immunotherapy to BCG has favorable outcomes in NMIBC

Video

“The notable finding was that the combination was well tolerated,” says Kelly L. Stratton, MD.

In this video, Kelly L. Stratton, MD, discusses the background, findings, and takeaways of the study, “Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABD trial,” presented at the 2021 American Urological Association Annual Meeting.

Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.